Yashpal Singh Rawat: Fortis Memorial Research Institute Made Its Positive Mark at ASH
Yashpal Singh Rawat, Vice President and Facility Director at Fortis Healthcare, shared on LinkedIn:
”Fortis Memorial Research Institute made its positive mark at ASH in USA !
It is a moment of immense pride for all of us at Fortis Memorial Research Institute, Gurugram to witness our institution represented on the global stage at the American Society of Hematology (ASH) 2025 Annual Meeting in Orlando, USA- the most prestigious and influential conference in the field of hematology.
Dr. Rahul Bhargava’s podium oral presentation on “Dissecting India’s Molecular Hematology Landscape: A 1000-patient genomic study” marks not just a scientific achievement but a defining milestone for FMRI.
Taking FMRI’s research from Gurugram to an international platform of this calibre reflects the depth, rigor, and innovation of the work being done here.
This recognition is a testament to the dedication of the entire molecular hematology team-the scientists, clinicians, technologists, and collaborators whose relentless efforts made this study possible.
Your commitment to advancing genomic medicine in India has now been acknowledged at the highest level in global hematology.
Congratulations to Dr. Rahul Bhargava for representing FMRI with excellence, and kudos to every team member who contributed to this landmark achievement.
This is just the beginning, and we look forward to many more such accomplishments that continue to position FMRI as a leader in cutting-edge hematology research.
Proud moment for FMRI.
Proud moment for Fortis Family.”
All from ASH25 featured in Hemostasis Today.
-
Dec 11, 2025, 16:18Caitlin Raymond’s Commentary on Artificial Intelligence in Transfusion Medicine is Out!
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report